<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01418547</url>
  </required_header>
  <id_info>
    <org_study_id>180/09</org_study_id>
    <nct_id>NCT01418547</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Torrent Pharmaceutical Limited's Isosorbide Mononitrate 120 mg ER Tablets Under Fed Conditions</brief_title>
  <official_title>An Open Label, Randomized, Two Treatment, Two Sequence, Two Period, Cross-over, Single-dose Comparative Oral Bioavailability Study of Isosorbide Mononitrate 120 mg ER Tablets (Test) of Torrent Pharmaceuticals Ltd., India and Isosorbide Mononitrate 120 mg ER Tablets (Reference) of Kremers Urban, USA in Healthy, Adult, Male, Human Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      Objective:

      to compare the single dose bioavailability of Torrent's Isosorbide Mononitrate 120 mg ER
      Tablets (Test) and Isosorbide Mononitrate 120 mg ER Tablets (Reference) of Kremers Urban, USA
      under fed condition. Dosing periods were separated by a washout period of 8 days.

      Study Design:

      randomized, two-way crossover, single-dose, open-label study in healthy human adult subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Bioequivalence based on Composite of Pharmacokinetics</measure>
    <description>Bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax.</description>
  </primary_outcome>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torrent's Isosorbide Mononitrate 120 mg ER Tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males within the age range of 18 to 55 years.

          -  A body mass index within 18-25 Kg/m2.

          -  Given written informed consent to participate in the study.

          -  Absence of diseases markers of HIV 1 &amp; 2, Hepatitis B &amp; C virus and RPR.

          -  Absence of significant disease or clinically significant abnormal laboratory values on
             laboratory evaluation, medical history and physical examination during the screening.

          -  A normal 12-lead ECG.

          -  A normal chest X-Ray.

          -  Comprehension of the nature and purpose of the study and compliance with the
             requirements of the entire protocol.

          -  No history or no evidence of hypersensitivity or idiosyncratic reactions to other
             nitrates or nitrites.

          -  No history of allergic rash.

          -  No history of significant systemic diseases.

          -  No history of psychiatric disorders or addiction to any recreational drug or drug
             dependence.

          -  No donation of blood within 56 days prior to study check-in.

          -  No participation in any clinical study within the past 56 days.

          -  No receipt of any prescription drugs or OTC products, with in two weeks prior to study
             check-in.

          -  No history of dehydration from diarrhea, vomiting or any other reason within a period
             of 24 hours prior to study check-in.

          -  No family history of neurological disorders.

          -  Not consumed alcohol and xanthine containing food and beverages, cigarettes and
             tobacco products, for at-list 48 hours, prior to study check-in.

          -  Negative results for drugs of abuse in urine and alcohol breath analysis during
             check-in of each period.

          -  Not consumed grape fruit juice within the 48 hours prior to study check-in.

        Exclusion Criteria:

          -  Blood pressure Systolic&gt; 140 mm Hg and &lt; 110 mm Hg Diastolic&lt; 70 mm Hg &gt; 90 mm Hg

          -  History of seizures

          -  History of alcohol consumption for more than 2 units/day.

          -  High caffeine or tobacco consumption

          -  History of difficulty with donating blood or difficulty in accessibility of veins.

          -  Any unusual or abnormal diet, for whatever reason e.g. fasting due to religious
             reasons.

          -  Used any pharmacological agents known to significantly induce or inhibit drug
             metabolizing enzymes within 14 days of the start of the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Trident Life sciences Limited</name>
      <address>
        <city>Hyderabad</city>
        <state>AP</state>
        <zip>500050</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trident Life Sciences Limited</name>
      <address>
        <city>Hydrabad</city>
        <state>AP</state>
        <zip>500050</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2011</study_first_posted>
  <last_update_submitted>August 16, 2011</last_update_submitted>
  <last_update_submitted_qc>August 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Investigator</name_title>
    <organization>Torrent Pharmaceuticals Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

